An American biotech has penned a strategic collaboration deal with Japan’s leading pharmaceutical company to pioneer therapies for neurological disorders.

The partnership between Wave Life Sciences and Takeda Pharmaceutical will see the pair combine on advancing treatment options for patients suffering from the likes of Alzheimer’s disease and Parkinson’s disease.

Takeda will invest more than $200 million in Wave, including a minimum of $60 million to support the biotech meet ‘multiple preclinical targets selected by and licensed to Takeda’.

“We are thrilled to be joining with Takeda in this ambitious alliance to bring meaningful therapies to patients suffering from devastating neurological diseases,” said Paul Bolno, President and Chief Executive Officer of Wave Life Sciences.